Your session is about to expire
← Back to Search
Nanoparticle-Enhanced Radiotherapy for Pancreatic Cancer
Study Summary
This trial is testing a new cancer treatment that combines a nanoparticle with radiation. They want to see if it's effective and safe for treating pancreatic cancer and lung tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You must have a visible and measurable disease that can be accurately measured.You have had allergic reactions to a specific type of contrast dye used for imaging tests.My cancer has spread to other parts of my body.I can take care of myself but might not be able to do heavy physical work.My lung cancer has not spread to my lymph nodes and cannot be removed by surgery.My cancer has not spread to distant parts of my body.I do not have active ulcers or cancer invading my bowel/stomach.My organ and bone marrow functions are normal.I've had radiation in my chest or abdomen that overlaps with where I'd get treatment now.I do not have any serious illnesses or social situations that would stop me from following the study's requirements.You have a stent in your duodenum.My cancer is a confirmed type of pancreatic cancer.I am 18 years old or older.My pancreatic cancer cannot be removed by surgery.My lung cancer or cancer spread to lungs is confirmed by tests.I am HIV-positive and not on antiretroviral therapy.You can't have an MRI scan due to specific reasons.I am not pregnant, as the study's medication may harm the baby.You have a severe fear of confined spaces or feel extremely anxious.I have completed 3 months of initial chemotherapy for advanced pancreatic cancer.My lung or pancreatic cancer is 5cm or smaller.We don't know how AGuIX might affect a growing baby inside the mother's belly.
- Group 1: SMART Phase 2
- Group 2: AGUIX + SMART Phase 1
- Group 3: AGUIX + SMART Phase 2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still places available for participants in this research?
"The clinical trial mentioned is still actively recruiting patients, with the most recent update being on October 31st, 2022. This information was first reported on May 27th, 2021."
What are researchers trying to learn from this clinical trial?
"The assessors of this study will monitor patients for 12 months to determine the maximum tolerated dose (MTD). Additionally, they will compare the R0 resection rate, serious adverse events at 12 months, and overall survival rate."
How many people fit the bill for this clinical trial's requirements?
"That is accurate. The clinicaltrials.gov website provides evidence that this trial, which was originally posted on May 27th 2021, 100 patients from 3 locations."
Share this study with friends
Copy Link
Messenger